{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T16:09:07Z","timestamp":1774022947861,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["2021JH2\/10300117"],"award-info":[{"award-number":["2021JH2\/10300117"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"Postdoctoral Science Foundation of China","doi-asserted-by":"crossref","award":["2018T111168"],"award-info":[{"award-number":["2018T111168"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-026-04229-2","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T23:04:03Z","timestamp":1770937443000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparisons of clinical patterns, short- and long-term prognostic outcomes in patients stratified by the severity of microvascular invasion after curative resection for hepatocellular carcinoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Zhenli","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuantong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuaishuai","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanzhi","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shixing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingshun","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"issue":"10461","key":"4229_CR1","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/S0140-6736(24)01771-9","volume":"404","author":"JK Wang","year":"2024","unstructured":"Wang JK, Liao R. Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial. Lancet. 2024;404(10461):1404\u20135.","journal-title":"Lancet"},{"issue":"1","key":"4229_CR2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12943-024-02101-z","volume":"23","author":"YT Chan","year":"2024","unstructured":"Chan YT, Zhang C, Wu J, et al. Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma. Mol Cancer. 2024;23(1):189.","journal-title":"Mol Cancer"},{"key":"4229_CR3","doi-asserted-by":"crossref","unstructured":"Mak LY, Liu K, Chirapongsathorn S et al. Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions. Nat Rev Gastroenterol Hepatol. 2024;21(12):834-51.","DOI":"10.1038\/s41575-024-00967-4"},{"issue":"4","key":"4229_CR4","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","volume":"21","author":"JM Llovet","year":"2024","unstructured":"Llovet JM, Pinyol R, Yarchoan M, et al. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nat Rev Clin Oncol. 2024;21(4):294\u2013311.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"4229_CR5","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ccell.2024.01.007","volume":"42","author":"X Yang","year":"2024","unstructured":"Yang X, Yang C, Zhang S, et al. Precision treatment in advanced hepatocellular carcinoma. Cancer Cell. 2024;42(2):180\u201397.","journal-title":"Cancer Cell"},{"issue":"12","key":"4229_CR6","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","volume":"20","author":"AG Singal","year":"2023","unstructured":"Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023;20(12):864\u201384.","journal-title":"Nat Rev Clin Oncol"},{"key":"4229_CR7","doi-asserted-by":"publisher","unstructured":"Fuster-Anglada C, Mauro E, Ferrer-F\u00e0brega J et al. Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection. J Hepatol. 2024. https:\/\/doi.org\/10.1016\/j.jhep.2024.06.018. (Epub).","DOI":"10.1016\/j.jhep.2024.06.018"},{"issue":"3","key":"4229_CR8","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/SLA.0000000000006386","volume":"280","author":"CJ Wehrle","year":"2024","unstructured":"Wehrle CJ, Hong H, Kamath S, et al. Tumor mutational burden from Circulating tumor DNA predicts recurrence of hepatocellular carcinoma after resection: an emerging biomarker for surveillance. Ann Surg. 2024;280(3):504\u201313.","journal-title":"Ann Surg"},{"issue":"8","key":"4229_CR9","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jamasurg.2024.1184","volume":"159","author":"A Vitale","year":"2024","unstructured":"Vitale A, Romano P, Cillo U, et al. Liver resection vs nonsurgical treatments for patients with early multinodular hepatocellular carcinoma. JAMA Surg. 2024;159(8):881\u20139.","journal-title":"JAMA Surg"},{"key":"4229_CR10","doi-asserted-by":"crossref","unstructured":"Wang F, Lu J, Yang T et al. Perioperative changes in serum transaminase levels: impact on postoperative morbidity following liver resection of hepatocellular carcinoma. Ann Surg. 2025;281(4):624-31.","DOI":"10.1097\/SLA.0000000000006235"},{"issue":"7","key":"4229_CR11","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.23.00757","volume":"42","author":"DQ Huang","year":"2024","unstructured":"Huang DQ, Hoang JK, Kamal R, et al. Antiviral therapy utilization and 10-Year outcomes in resected hepatitis B Virus- and hepatitis C Virus-Related hepatocellular carcinoma. J Clin Oncol. 2024;42(7):790\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4229_CR12","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/SLA.0000000000003268","volume":"273","author":"S Lee","year":"2021","unstructured":"Lee S, Kang TW, Song KD, et al. Effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation. Ann Surg. 2021;273(3):564\u201371.","journal-title":"Ann Surg"},{"issue":"10","key":"4229_CR13","doi-asserted-by":"publisher","first-page":"e182721","DOI":"10.1001\/jamasurg.2018.2721","volume":"153","author":"Z Li","year":"2018","unstructured":"Li Z, Lei Z, Xia Y, et al. Association of preoperative antiviral treatment with incidences of microvascular invasion and early tumor recurrence in hepatitis B Virus-Related hepatocellular carcinoma. JAMA Surg. 2018;153(10):e182721.","journal-title":"JAMA Surg"},{"issue":"4","key":"4229_CR14","doi-asserted-by":"publisher","first-page":"e230657","DOI":"10.1148\/radiol.230657","volume":"307","author":"RM Summers","year":"2023","unstructured":"Summers RM. Radiomics to predict microvascular invasion in hepatocellular carcinoma: A promising biomarker for tumor recurrence. Radiology. 2023;307(4):e230657.","journal-title":"Radiology"},{"issue":"3","key":"4229_CR15","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41591-023-02786-7","volume":"30","author":"K Wang","year":"2024","unstructured":"Wang K, Xiang YJ, Yu HM, et al. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nat Med. 2024;30(3):708\u201315.","journal-title":"Nat Med"},{"issue":"1","key":"4229_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/hbsn-22-411","volume":"13","author":"LQ Yao","year":"2024","unstructured":"Yao LQ, Li C, Diao YK, et al. Grading severity of microscopic vascular invasion was independently associated with recurrence and survival following hepatectomy for solitary hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2024;13(1):16\u201328.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"4","key":"4229_CR17","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1097\/JS9.0000000000000325","volume":"109","author":"XF Xu","year":"2023","unstructured":"Xu XF, Diao YK, Zeng YY, et al. Association of severity in the grading of microvascular invasion with long-term oncological prognosis after liver resection for early-stage hepatocellular carcinoma: a multicenter retrospective cohort study from a hepatitis B virus-endemic area. Int J Surg. 2023;109(4):841\u20139.","journal-title":"Int J Surg"},{"issue":"6","key":"4229_CR18","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1007\/s12072-020-10111-4","volume":"14","author":"X Sheng","year":"2020","unstructured":"Sheng X, Ji Y, Ren GP, et al. A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC. Hepatol Int. 2020;14(6):1034\u201347.","journal-title":"Hepatol Int"},{"issue":"10","key":"4229_CR19","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.humpath.2010.12.016","volume":"42","author":"N Fujita","year":"2011","unstructured":"Fujita N, Aishima S, Iguchi T, et al. Histologic classification of microscopic portal venous invasion to predict prognosis in hepatocellular carcinoma. Hum Pathol. 2011;42(10):1531\u20138.","journal-title":"Hum Pathol"},{"issue":"6","key":"4229_CR20","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1097\/TP.0000000000000489","volume":"99","author":"T Iguchi","year":"2015","unstructured":"Iguchi T, Shirabe K, Aishima S, et al. New pathologic stratification of microvascular invasion in hepatocellular carcinoma: predicting prognosis after Living-donor liver transplantation. Transplantation. 2015;99(6):1236\u201342.","journal-title":"Transplantation"},{"issue":"3","key":"4229_CR21","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1053\/j.gastro.2009.06.003","volume":"137","author":"S Roayaie","year":"2009","unstructured":"Roayaie S, Blume IN, Thung SN, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology. 2009;137(3):850\u20135.","journal-title":"Gastroenterology"},{"issue":"12","key":"4229_CR22","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.3390\/cancers12123868","volume":"12","author":"A Giani","year":"2020","unstructured":"Giani A, Cipriani F, Famularo S, et al. Performance of comprehensive complication index and Clavien-Dindo complication scoring system in liver surgery for hepatocellular carcinoma. Cancers (Basel). 2020;12(12):3868.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4229_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1245\/s10434-012-2513-1","volume":"20","author":"M Rodr\u00edguez-Per\u00e1lvarez","year":"2013","unstructured":"Rodr\u00edguez-Per\u00e1lvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP, Burroughs AK. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol. 2013;20(1):325\u201339.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"4229_CR24","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1245\/s10434-013-3376-9","volume":"21","author":"S Sumie","year":"2014","unstructured":"Sumie S, Nakashima O, Okuda K, et al. The significance of classifying microvascular invasion in patients with hepatocellular carcinoma. Ann Surg Oncol. 2014;21(3):1002\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"10415","key":"4229_CR25","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chen M, Cheng AL, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402(10415):1835\u201347.","journal-title":"Lancet"},{"key":"4229_CR26","doi-asserted-by":"crossref","unstructured":"Ma T, Bai X, Zhang Q et al. Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: A randomized, open-label, phase 3 trial. Hepatology. 2025;82(5):1112-21.","DOI":"10.1097\/HEP.0000000000001233"},{"issue":"6","key":"4229_CR27","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s12072-024-10732-z","volume":"18","author":"G Lau","year":"2024","unstructured":"Lau G, Obi S, Zhou J, et al. APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024. Hepatol Int. 2024;18(6):1661\u201383.","journal-title":"Hepatol Int"},{"issue":"2","key":"4229_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"EASL Clinical Practice","year":"2025","unstructured":"EASL Clinical Practice. Guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82(2):315\u201374.","journal-title":"J Hepatol"},{"issue":"1","key":"4229_CR29","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/HEP.0000000000001269","volume":"82","author":"TH Taddei","year":"2025","unstructured":"Taddei TH, Brown DB, Yarchoan M, Mendiratta-Lala M, Llovet JM. Critical update: AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2025;82(1):272\u20134.","journal-title":"Hepatology"},{"issue":"3","key":"4229_CR30","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1159\/000540857","volume":"14","author":"X Bi","year":"2025","unstructured":"Bi X, Lu Y, Chen B, et al. Chinese expert consensus on the combination of targeted therapy and immunotherapy with locoregional therapy for Intermediate\/Advanced hepatocellular carcinoma. Liver Cancer. 2025;14(3):334\u201350.","journal-title":"Liver Cancer"},{"issue":"2","key":"4229_CR31","doi-asserted-by":"publisher","first-page":"246","DOI":"10.21037\/hbsn-24-359","volume":"14","author":"J Sun","year":"2025","unstructured":"Sun J, Xia Y, Shen F, Cheng S. Chinese expert consensus on the diagnosis and treatment of hepatocellular carcinoma with microvascular invasion (2024 edition). Hepatobiliary Surg Nutr. 2025;14(2):246\u201366.","journal-title":"Hepatobiliary Surg Nutr"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04229-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04229-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04229-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:20:38Z","timestamp":1774020038000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04229-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4229"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04229-2","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work is approved by the Ethics Committee of the General Hospital of Northern Theater Command (No: 2024295).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Approved by each author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}